NDAORALCAPSULE
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
RIMACTANE (rifampin) by Oxford Drug Design is clinical pharmacology oral administration rifampin is readily absorbed from the gastrointestinal tract. Approved for asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx, meningococcal infection because of the possibility of the rapid emergence of resistant organisms (see ), the treatment of all forms of tuberculosis. First approved in 1971.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIMACTANE (rifampin) is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase in susceptible Mycobacterium tuberculosis organisms. It is a first-line agent for treating all forms of tuberculosis and is used to eliminate meningococci from the nasopharynx in asymptomatic carriers of Neisseria meningitidis. The drug is well-absorbed orally, widely distributed throughout body tissues including cerebrospinal fluid, and has a half-life of 2–3 hours with repeated dosing.
LOE Approaching
This product is approaching loss of exclusivity, signaling a contracted commercial infrastructure and reduced headcount demands on the brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY Oral Administration Rifampin is readily absorbed from the gastrointestinal tract. Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual. Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum…
Worked on RIMACTANE at Oxford Drug Design? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.